FDA Approves New Drugs Faster Than Five International Agencies

International Pharmaceutical Regulatory Monitor
A A
The increased use of fast track regulatory pathways has led to the FDA having the shortest median approval time for new active drug substances in 2017 compared to five other international regulatory agencies, according to the UK-based Centre for Innovation in Regulatory Science (CIRS).

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor